Full-Time

Senior Director

Clinical Development

Celgard

Celgard

201-500 employees

High-performance membranes for energy storage

Compensation Overview

$300k - $350k/yr

+ Performance-based bonus

Cary, NC, USA

Hybrid

Approximately 25% domestic and international travel required.

PharmD, PhD, MD, Doctor of Osteopathic Medicine (DO)

Category
Biology & Biotech (1)
Required Skills
Word/Pages/Docs
Biostatistics
Excel/Numbers/Sheets

Get referred to Celgard

See people who can refer or advise you

Requirements
  • An MD, DO, PhD, PharmD, or equivalent degree or experience is required.
  • At least 7-10 years of demonstrated clinical research and clinical development experience is required, including experience with all drug and medical device development phases.
  • Working knowledge of the assigned disease area is required, with the ability to interpret, discuss, and present efficacy and safety data relating to clinical trials.
  • Working knowledge of region-specific regulatory guidelines, including FDA, EMEA, and PMDA guidelines, and ICH-GCP guidelines is required.
  • Working knowledge of clinical trial design and statistics is required.
  • Understanding of scientific methods and tools used in early clinical development, biomarkers, translational modeling, biostatistics, and the relevant clinical trial landscape is required.
  • Ability to work in a cross-functional and global organization is required.
  • Ability to work within international environments with team members located in different locations and countries is required.
  • Ability to understand and clarify boundaries of responsibility, allocate decision-making authority, and assign task responsibilities to other team members is required.
  • Ability to efficiently manage all tasks required during a study, track multiple items, and provide guidance on task prioritization within a study is required.
  • Ability to travel domestically and internationally, approximately 25%, is required.
  • Strong project management and medical writing skills are required.
  • Proficiency in Microsoft Office Suite, including Word, Excel, and PowerPoint, and Adobe Pro is required.
Responsibilities
  • Prepare clinical development plans according to the nature and objectives of the clinical project while ensuring compliance with ICH-GCP, medical device guidelines and regulations, and agreed quality standards.
  • Manage the overall product portfolio, including multiple indications for the same product, as needed based on the clinical development plan.
  • Oversee protocol development from concept to final protocol and protocol execution, including interaction with key opinion leaders and investigators.
  • Serve as an escalation point for the Clinical Development team and participate in CRO Executive Governance meetings as required.
  • Serve as a mentor and provide line management for junior-level staff, if required.
  • Manage budgetary responsibilities for programs overseen by direct reports.
  • Serve as Medical Monitor or point of contact for a CRO Medical Monitor for assigned clinical trials, overseeing participant inclusion, and provide backup medical-monitoring support for direct reports as required.
  • Write, edit, and review medical and scientific elements of internal and external documents, including clinical research documents, clinical development plans, operational and regulatory documents, study synopses, protocols, case report forms, informed consent templates, feasibility assessments, statistical analysis plans, clinical sections of regulatory documents, key study plans, and clinical study reports.
  • Lead responses to competent-authority questions as requested.
  • Oversee study data reviews, liaise with data safety monitoring committees and other protocol-directed committees, oversee data analysis, and oversee clinical study report authoring.
  • Participate in multidisciplinary project teams as the responsible individual for project clinical development and presentation of clinical trial results, aligned with Program Management when appropriate.
  • Oversee or conduct ongoing medical and scientific review of clinical-trial data with clinical scientific experts.
  • Oversee creation and translation of the Target Product Profile into clinical strategy.
  • Manage Key Opinion Leader and Medical Advisory Board interactions and identify Key Opinion Leaders as needed.
  • Manage study medical and safety data aspects and risk-benefit assessments with support from the Pharmacovigilance team.
  • Ensure study quality and manage internal clinical activities.
  • Assist Clinical Operations with supervision of contract research organization activities by reviewing key study plans and performance and quality, and lead risk-mitigation activities to ensure timely delivery of study results and reports compliant with applicable quality requirements.
  • Escalate areas of concern to Clinical Development and Clinical Operations Heads as appropriate.
  • Support business-development activities, due-diligence processes, and market access related to clinical development.
  • Supervise clinical-trial activities delegated to or shared with the Clinical Project Manager.
Desired Qualifications
  • Experience in Infectious Disease is preferred.

Celgard makes and sells high-performance membrane materials and thin separators used inside batteries, as well as fabrics for outdoor apparel and medical PPE. The membranes sit between battery electrodes to prevent contact while allowing ions to pass, enabling safe and efficient operation in lithium-ion and other chemistries. The company stands out through its Asahi Kasei Group affiliation and strategic alliances (such as with Æsir Technologies) to pursue new battery chemistries, while expanding manufacturing capacity. Its goal is to provide reliable membranes and protective fabrics at scale to support safer, longer-lasting energy storage and protective textiles, and to drive industry growth through collaborations.

Company Size

201-500

Company Stage

N/A

Total Funding

N/A

Headquarters

Charlotte, North Carolina

Founded

N/A

Get referred to Celgard

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 2026 Concord coating launch expands multilayer coated separators for EVs and storage.
  • Charlotte operations start in 2026, adding about 100 jobs and more domestic capacity.
  • 2025 Daramic divestiture sharpened Asahi Kasei’s battery focus behind Celgard’s lithium-ion business.

What critics are saying

  • Senior China settlement ended headlines, but trade-secret warfare resumes with every separator launch.
  • Entek, Semcorp, and Microporous are expanding North American capacity faster than Celgard.
  • If Asahi Kasei shifts investment toward Hipore and Japan, Celgard becomes an afterthought.

What makes Celgard unique

  • Celgard invented ceramic-coated separators; competitors still license against that benchmark.
  • Charlotte and Concord combine dry-process membranes with new coating lines for customized EV products.
  • Asahi Kasei backs Celgard with North American capital, manufacturing, and global battery customers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Company News

Best Magazine
May 26th, 2026
Celgard celebrates 15 years at Concord site, expands separator coating capability.

Celgard celebrates 15 years at Concord site, expands separator coating capability. 26 May 2026 Celgard has launched new coating capabilities at its Concord, North Carolina manufacturing facility as the lithium-ion battery separator manufacturer marked the site's 15th anniversary. The company said the expansion adds new "state-of-the-art" coating technology capable of producing functional coatings, multilayer coated separators (MCS) and other customised separator products for lithium-ion batteries. According to the company, its new capabilities support a range of coating patterns, thicknesses, coverage levels and multilayer structures, while remaining compatible with multiple base-film technologies. The company said this would enable the development of more tailored separator products for electric vehicles, stationary energy storage systems and next-generation battery applications. Celgard's second US manufacturing site. The Concord plant opened in 2011 as Celgard's second US manufacturing site and forms part of the company's North American manufacturing network. The announcement comes amid the separation of Celgard and lead-acid battery separator specialist Daramic following the sale of Daramic by parent company Asahi Kasei. Celgard describes itself as the original inventor of ceramic-coated separators (CCS), a technology widely used in lithium-ion batteries to improve thermal stability and safety performance. "With our global footprint especially deeply rooted in US, we are excited to drive the LIB industry to a new level with our partners," the company said. Photo: Employees at the Concord facility were joined by local business leaders and government representatives for a ribbon-cutting ceremony marking the launch of the new coating capabilities. Credit: Celgard

Yahoo Finance
Jan 29th, 2024
Celgard and Æsir Technologies Forge Strategic Alliance to Drive Industry Innovation in Nickel-Zinc, Zinc-Air and Lithium-Zinc Batteries

Together, Celgard and Æsir will collaborate on joint research projects to further develop high-technology next-generation Nickel-Zinc (Ni-Zn), Zinc-Air (Zn-Air), Lithium-Zinc (Li-Zn) and Sodium-Zinc (Na-Zn) batteries used primarily in aviation, data centers, telecom, energy infrastructure and electric vehicle (EV) charging applications.

Plant Services
Nov 30th, 2023
Celgard expands North Carolina manufacturing plant to support electric vehicle supply chain

Celgard, LLC has announced plans to expand its manufacturing facility in Charlotte, North Carolina, generating 100 new jobs in the process.

PR Newswire
Oct 31st, 2023
Celgard Charlotte Manufacturing Facility To Expand Battery Separator Capacity And Create New Jobs

Celgard to expand facilities, workforce and product portfolio to better serve the EV battery separator supply chain. Post thisThe Biden-Harris Administration and the U.S. Department of Energy (DOE) have identified the domestic U.S. battery market as a critical supply chain focus area for the nation. Investments in Celgard's Charlotte plant will allow the company to expand existing infrastructure to quickly meet demand of the lithium-ion battery (LIB) separator supply chain and domestic customers.Celgard manufactures dry-process membrane separator also used in vehicle electrification. The company already has a skilled employee base capable of applying technical coatings to base film shipped from Hipore™ sister locations and completing finishing steps required to meet customer specifications

Tamarindo
Jun 13th, 2023
Celgard & Lithion Battery form battery storage alliance | Tamarindo

US-headquartered Celgard, a subsidiary of Polypore International, has formed a strategic alliance with Lithion Battery, whereby the two companies will undertake joint development of battery separators for lithium-ion cells for energy storage systems and microgrids.